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Abstract
The CONSORT Statement was developed to help authors improve the quality of reporting randomized trials. To
augment the statement we published the CONSORT explanation and elaboration paper which included at least
one example of good reporting for each CONSORT checklist item. We are developing a comprehensive database
of examples of good reporting for each checklist item to take advantage of the breadth and variety of trials
familiar to authors and readers globally. We invite authors, editors, and readers worldwide to nominate examples of
well reported items for the database.
Randomized trials are critically important to healthcare,
widely regarded as providing the most reliable evidence
on the benefits and harms of interventions. Reports of
many randomized trials, most of which are published in
specialty and subspecialty journals, have crucial informa-
tion missing or reported in such a manner that the
information cannot be understood and/or used by read-
ers [1]. While improvements have been seen over time,
the majority of trials still do not report essential infor-
mation available from every trial such as full details of
the interventions and outcomes, and the methods of
allocation of interventions. Glasziou and colleagues
reported that only two thirds of the 55 reports of rando-
m i z e dt r i a l st h e ye x a m i n e dp r o v i d e ds u f f i c i e n td e t a i l s
about the interventions such that clinicians could use
them in practice [2]. Hopewell and colleagues examined
reports of 616 trials published in December 2006 and
n o t e dt h a to n l y3 4 %d e s c r i bed how the randomization
sequence was generated and only 25% described an ade-
quate method of allocation concealment; despite
improvement since 2000 both remain well under 50%
[1]. These examples focus on internal validity. Reporting
of issues pertaining to external validity is equally dis-
couraging, if not worse [3,4]. One consequence of
unclear trial reports is their potential exclusion from
systematic reviews. Clearly, the importance of including
this critical information is not appreciated by authors,
peer reviewers, or editors.
The CONSORT Statement was developed to help
authors improve reporting their randomized trials.
CONSORT was first published in 1996 and updated,
initially in 2001 and most recently in March 2010 [5]. A
systematic review indicated that journal endorsement of
CONSORT is associated with improvements in report-
ing of randomized trials [6].
An innovative feature of CONSORT 2001 was the
development of the CONSORT explanation and ela-
boration (E&E) paper, also updated in 2010 [7]. A dis-
tinctive feature of the E&E paper was inclusion of at
least one example of good reporting for each of the
checklist items. For example, Appendix 1 shows exam-
ples in the E&E of good reporting of trial interventions
and sequence generation. The inclusion of an example
in the E&E indicates that for that trial this specific item
was reported well (but it does not imply that the entire
article was necessarily a good trial report).
Readers of a report of an RCT need to know how the
trial was carried out - clear and complete reporting
reveals essential details of trial design and conduct. That
information may sometimes reveal some aspects of the
trial that were less than ideal. Likewise, readers need a
clear presentation of the trial’s main findings, in line
with the trial protocol. Good reporting provides readers
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weaknesses affect the reliability of the trial findings.
Selecting the examples included in the updated CON-
SORT 2010 E&E document was a time consuming pro-
cess, as our goal was to identify examples of both good
reporting and good methodology. Moreover, we could
not take full advantage of the breadth and variety of
published randomized trials familiar to authors and
readers globally. To enhance this resource for authors of
randomized trial reports, we intend to develop an exten-
sive, searchable, comprehensive database, accessible on
the CONSORT website http://www.consort-statement.
org, of examples of good reporting for each CONSORT
checklist item (e.g., 6a, Outcomes). In order to achieve
this, the CONSORT Group is inviting authors, editors,
and readers worldwide to nominate examples from pub-
lished reports of trials of well reported items to be con-
sidered for inclusion in the database. Our initial focus is
on good reports of sound conduct, as in the E&E paper.
Examples of good reporting should be submitted via
e-mail to the CONSORT Examples Library web page
http://www.consort-statement.org/consort-library of the
CONSORT website. Along with the example submis-
sions, authors will be asked to include their name and
e-mail address for correspondence, if we need clarifica-
tion. The only specific criterion for selecting examples is
the consensus view that the example is a good report of
the item in question. We do not anticipate correspond-
ing with authors, editors, or readers of items included in
the database or those items not selected; this would be
time consuming given the very limited resources avail-
able to the CONSORT group. We plan to include a list
of contributors in the CONSORT database. We hope
that this expanded database of examples will further
help authors in complying with the CONSORT 2010
Statement as they write up their trial findings for publi-
cation. We look forward to hearing from you.
Appendix 1
Examples of good reporting for two items in the CON-
SORT checklist
CONSORT item 6: “The interventions for each
group with sufficient details to allow replication,
including how and when they were actually
administered”
Example of a good description of an intervention:
“Patients were randomly assigned to receive a custom-
made neoprene splint to be worn at night or to usual
care. The splint was a rigid rest orthosis recommended
for use only at night. It covered the base of the thumb
and the thenar eminence but not the wrist [picture
shown]. Splints were made by 3 trained occupational
therapists, who adjusted the splint for each patient so
that the first web could be opened and the thumb
placed in opposition with the first long finger. Patients
were encouraged to contact the occupational therapist if
they felt that the splint needed adjustment, pain
increased while wearing the splint, or they had adverse
effects (such as skin erosion). Because no treatment can
be considered the gold standard in this situation,
patients in the control and intervention groups received
usual care at the discretion of their physician (general
practitioner or rheumatologist). We decided not to use a
placebo because, to our knowledge, no placebo for
splinting has achieved successful blinding of patients, as
recommended” [8].
CONSORT item 8a “Method used to generate the
random allocation sequence”
Example of a good description of sequence generation
for simple randomization:
“Independent pharmacists dispensed either active or
placebo inhalers according to a computer generated ran-
domisation list” [9].
More complex types of randomization exist, such as
blocked randomization, although we did not include
examples in the CONSORT 2010 E&E paper.
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